Le Lézard
Classified in: Health, Science and technology

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 32,000 shares of Puma common stock to six new non-executive employees.

The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2020, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.


These press releases may also interest you

at 02:53
The automotive technology company Veoneer, Inc. , has partnered with Subaru to introduce the new generation EyeSight on the all-new Subaru Levorg.  Veoneer will begin producing systems for the Japan market starting later this year.      Veoneer was...

at 02:51
Elbit Systems Ltd.  ("Elbit Systems" or the "Company") announced today that it was awarded a contract valued at approximately $33 million to supply tactical radio systems to a customer in Asia-Pacific. The contract will be performed over a 12-month...

at 02:11
Itiviti, a leading technology, and service provider of electronic trading and connectivity solutions to financial institutions worldwide, today announced that Itiviti's sell-side OMS has won Best Equity Trading System of the Year at the FOW Asia...

at 02:05
PureTech Health plc (LSE:PRTC) ("PureTech"), a clinical stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the appointment of biotech...

at 02:05
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced positive top-line...

at 02:05
It is with great pleasure that Juniper Research announces the 2020 winners of the Future Digital Awards for Fintech & Payments. This category recognises the most impactful financial products and services operating across numerous areas, including:...



News published on 10 august 2020 at 17:20 and distributed by: